We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Telesis Bio Inc | NASDAQ:TBIO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1169 | 3.39% | 3.5669 | 3.47 | 3.60 | 3.67 | 3.33 | 3.45 | 32,843 | 23:24:06 |
From May 2021 to May 2024
By Kim Richters
French healthcare major Sanofi has agreed to acquire Translate Bio Inc. in a deal that gives the mRNA-therapeutics company a total equity value of around $3.2 billion.
The two companies, which have been working on a mRNA Covid-19 vaccine candidate together, said on Tuesday that Sanofi would acquire all of Translate Bio's outstanding shares for $38.00 a share in cash. The price represents a premium of 56% to Translate Bio's volume-weighted average price a share of the past 60 days, they said.
The boards of directors of both companies approved the deal and Translate Bio's chief executive officer and its largest shareholder The Baupost Group, LLC have agreed to support the offer, the companies said.
"Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology, and rare diseases in addition to vaccines," Sanofi Chief Executive Paul Hudson said.
Sanofi's tender offer is planned to start later this month and it expects the takeover of the U.S. company to be completed in the third quarter.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
August 03, 2021 01:47 ET (05:47 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Telesis Bio Chart |
1 Month Telesis Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
